Cargando…
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are si...
Autores principales: | Park, Jonathan J., Codina, Adan, Ye, Lupeng, Lam, Stanley, Guo, Jianjian, Clark, Paul, Zhou, Xiaoyu, Peng, Lei, Chen, Sidi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716677/ https://www.ncbi.nlm.nih.gov/pubmed/36456981 http://dx.doi.org/10.1186/s13045-022-01389-y |
Ejemplares similares
-
In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens
por: Chow, Ryan D., et al.
Publicado: (2019) -
In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
por: Ye, Lupeng, et al.
Publicado: (2019) -
CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019) -
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro
por: Liu, Ming, et al.
Publicado: (2023) -
Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)